Vytrus Biotech closed the first quarter of 2025 with a business figure of 2.1 million euros, it translates into a growth of 76% and its EBITDA increased by 102%, located at 1.02 million euros, thanks to the operational leverage corresponding to the increase in income.
He Strategic Plan 2024–2027 Vytrus Biotech is based on two pillars: becoming a multitecnological company and strengthening the direct relationship with the final customer. The objectives in financial terms contemplate some Sales of 12 million euros in 2027Most based on plant stem cells and an ebitda of 5 million euros with a 1x financial/ebitda debt ratio.
To do this, the company will carry out a series of measures that will boost its growth: launch of 10 new products between 2024 and 2027, strategic alliances that allow it to increase its portfolio and grow at an organic level acquiring companies that allow access to complementary technologies.
Invertión and Innovación
The engine of this growth has been innovation in R&D. The discovery and repositioning of exosomal peptides in historical products has improved the effectiveness of its active ingredients and has promoted sales acceleration.
The investment in R&D D+I reached 1 million euros in 2024 and is expected to grow up to 1.3 million euros in 2027, being aligned with the objectives of the strategic plan and representing 13% of sales in 2027.
Recommendation
GVC GAESCO raises its target price at 4.65 EUR per share by December 2025, compared to the current 3.10 EUR of current contribution, which represents a bullish potential of +50.0%. Its recommendation remains to “buy”, supported by the execution of its strategic plan, the strong impulse of sales and Ebitda, and an attractive assessment in terms of per and EV/EBITDA.